The latest price target for Orgenesis (NASDAQ:ORGS) was reported by Benchmark on June 14, 2023. The analyst firm set a price target for $6.00 expecting ORGS to rise to within 12 months (a possible 717.88% upside). 0 analyst firms have reported ratings in the last year.

The latest analyst rating for Orgenesis (NASDAQ:ORGS) was provided by Benchmark, and Orgenesis reiterated their speculative buy rating.

There is no last upgrade for Orgenesis

There is no last downgrade for Orgenesis.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Orgenesis, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Orgenesis was filed on June 14, 2023 so you should expect the next rating to be made available sometime around June 14, 2024.

While ratings are subjective and will change, the latest Orgenesis (ORGS) rating was a reiterated with a price target of $0.00 to $6.00. The current price Orgenesis (ORGS) is trading at is $0.73, which is within the analyst’s predicted range.